#122 Why AI Drug Discovery Is So Hard — Dr Imran Haque (Recursion)

Despite $billions of investment into the sector — there are still no AI discovered drugs on the market. Why? Recursion Pharmaceuticals (NASDAQ: RXRX) is one of the hottest AI drug discovery companies on the market. Especially after NVIDIA's $50M investment into them. Dr Imran Haque (SVP of AI and Digital Sciences) explains why AI drug discovery is so tricky — and when it's arriving. 0:00 Intro 0:42 Decoding biology (the big idea) 2:18 Why is AI drug discovery harder than it looks? 4:48 Simulating the Sims (game) vs AI drug discovery 6:58 Building data for AI drug discovery 14:47 Recursion's successes and failures 24:22 The barriers to AI drug discovery 26:45 How optimistic should we be about AI drug discovery 35:26 Being aggressively generalist for success People Dr Imran Haque: https://www.recursion.com/team-members/imran-haque Dr Imran Mahmud: https://www.imranmahmud.com/ Dr Mustafa Sultan: https://www.musty.io/